Multiple Myeloma Support + Trials

What's the purpose of this trial?

This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.

This trial is currently open and accepting patients.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

Patients must be able to provide written informed consent
A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care
Age ≥ 18 years;
Documented hematologic malignancy (any of the below):
1. MM
2. ALL (B and T-cell subtypes)
3. B-cell NHL (all sub types)
4. CLL
5. Other lymphoid malignancies (upon review and approval by study chair)

Exclusion Criteria:

Patients must not meet any of the following criteria in order to be enrolled into the study:

Concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol
A decision has been made by the treating provider to not use the clonoSEQ Assay as part of routine clinical care